PATH Stock Slides As Traders Question AI Growth Story

UiPath Inc. stocks have been trading down by -4.01 percent amid reports of slowing automation demand and competitive pressures.

Live Update At 15:02:57 EDT: On Wednesday, September 16, 2026 UiPath Inc. stock [NYSE: PATH] is trending down by -4.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

PATH has been in a steady downtrend since late August. The stock traded near $18.50 at the end of the month and now sits around $13.67, a slide of roughly 25%. For active traders, that is a clear sign sentiment flipped hard after earnings.

The daily chart shows a sharp gap down in early September, then a grind lower with weak bounces. PATH tried to hold the $16s and then the $15s, but each support level broke, turning into resistance. That tells traders sellers are still in control.

Intraday on the latest session, PATH mostly chopped between $13.65 and $13.90, with tight five‑minute candles and no real trend. That type of low‑range action often means the big flush already happened and the stock is catching its breath.

Fundamentally, UiPath posted quarterly revenue of about $410M and net income of roughly $36M. Gross margin near 83% shows a strong software model, and PATH posted positive free cash flow of about $29M. But with a price‑to‑sales ratio around 4.6 and a P/E near 24, the market still expects growth. When a “growth” name misses the narrative, traders punish it quickly—as PATH just showed.

Why Traders Are Watching PATH Now

PATH is sitting at the crossroads of hype and reality. UiPath sells automation software wrapped in an AI pitch, but the latest quarter made traders question how much that AI story is actually translating into durable growth.

The earnings release triggered a brutal reaction: PATH fell in a range of 11%–17% as the market repriced expectations. That sort of single‑day hit usually means funds and larger players decided the growth profile no longer matched the old valuation. For short‑term traders, that is exactly the kind of shock that creates both opportunity and danger.

Bank of America nudged its PATH price target from $13 to $15 after mixed fiscal Q2 numbers, yet kept an Underperform rating. The message is clear: even with slightly better margin assumptions, BofA does not see AI meaningfully accelerating annual recurring revenue right now. When a major bank raises the target but still tells clients to stay cautious, momentum traders listen.

RBC added another headwind for PATH. The firm called out UiPath, along with other application‑focused software names, as lagging groups while money rotates into cyber, infrastructure, and data plays that look more central to AI build‑outs. That sector rotation matters. Even if UiPath executes well, PATH shares may struggle to expand their multiple while traders prefer other AI angles.

Layer on top the insider move: CEO Daniel Dines sold about 1.4 million PATH shares, roughly $22.5M in value, while still holding around 26.5 million Class A shares. He remains heavily exposed, but large sales into a weak tape rarely boost confidence. For active traders, this combination of earnings disappointment, cautious Wall Street calls, sector rotation, and insider selling explains why PATH is under such heavy pressure.

Conclusion

For traders, PATH is now a classic “fallen growth story” setup. UiPath still has real revenue—about $1.61B over the trailing year—and solid software economics with high gross margins and positive free cash flow. The balance sheet carries very little debt and more than $1.2B in cash and short‑term investments, giving PATH plenty of runway.

But the market no longer pays just for potential. The sharp 11%–17% post‑earnings drop shows traders are questioning UiPath’s ability to turn the AI buzz into sustained ARR acceleration. BofA’s Underperform rating and RBC’s criticism of application‑focused software signal that big money is positioning defensively around PATH and its peers.

From a trading standpoint, PATH now trades below recent support in the mid‑teens, with $14–$15 acting as a clear resistance zone. Until UiPath proves the growth story again, PATH is likely to behave like a broken chart: sharp pops on short covering, followed by fast fades as sellers reload.

This is where discipline matters. As Tim Sykes often says, “The market rewards prepared traders and punishes the lazy ones.” As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.”. For PATH, that means respecting the downtrend, watching key levels intraday, and cutting losses fast if a bounce fails. UiPath remains a well‑known AI automation name, but right now PATH is a sentiment story, and sentiment is firmly on the bearish side. This analysis is for educational and research use only, not trading advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks